作者
Sarah Picaud, David Da Costa, Angeliki Thanasopoulou, Panagis Filippakopoulos, Paul V Fish, Martin Philpott, Oleg Fedorov, Paul Brennan, Mark E Bunnage, Dafydd R Owen, James E Bradner, Philippe Taniere, Brendan O'Sullivan, Susanne Müller, Juerg Schwaller, Tatjana Stankovic, Stefan Knapp
发表日期
2013/6/1
期刊
Cancer research
卷号
73
期号
11
页码范围
3336-3346
出版商
American Association for Cancer Research
简介
Bromo and extra terminal (BET) proteins (BRD2, BRD3, BRD4, and BRDT) are transcriptional regulators required for efficient expression of several growth promoting and antiapoptotic genes as well as for cell-cycle progression. BET proteins are recruited on transcriptionally active chromatin via their two N-terminal bromodomains (BRD), a protein interaction module that specifically recognizes acetylated lysine residues in histones H3 and H4. Inhibition of the BET–histone interaction results in transcriptional downregulation of a number of oncogenes, providing a novel pharmacologic strategy for the treatment of cancer. Here, we present a potent and highly selective dihydroquinazoline-2-one inhibitor, PFI-1, which efficiently blocks the interaction of BET BRDs with acetylated histone tails. Cocrystal structures showed that PFI-1 acts as an acetyl-lysine (Kac) mimetic inhibitor efficiently occupying the Kac binding …
引用总数
2013201420152016201720182019202020212022202320247284337431929311912146
学术搜索中的文章